Evaluating organ-specific responses to ADCs in metastatic breast cancer

Antibody Drug Conjugates in Metastatic Breast Cancer | Anthony Elias, MD | ESMO22 ColoradoПодробнее

Combination therapies incorporating ADCs in breast cancerПодробнее

Experts discuss Antibody-Drug Conjugates in Breast, Lung, & GI Cancers - https://bit.ly/3rKKvzMПодробнее

Novel antibody-drug conjugates (ADCs) technologies for management of mBCПодробнее

Emerging Antibody-Drug Conjugates in Breast Cancer: An Expert Analysis of Promising TherapiesПодробнее

Educational Sessions: "Understanding the anti-cancer immune response: Innate and adaptive..."Подробнее

Evaluating the Evidence and Parsing the Practicalities of Therapeutic Choices in HR+ Breast CancerПодробнее

ADC’s - What Everyone with MBC Should Know about Antibody Drug ConjugatesПодробнее

Where are we in sequencing ADCs in HR+ breast cancer?Подробнее

Resistance to ADCs in breast cancer and novel combination strategiesПодробнее

Antibody Drug Conjugates in Metastatic Breast Cancer | Sramila Aithal, MD | ESMO22 PennsylvaniaПодробнее

Antibody-drug conjugates for the treatment of breast cancerПодробнее

The latest clinical research on ADCs in breast cancerПодробнее

Evaluating the Role of Liquid Biopsy in Breast CancerПодробнее

Metastatic Breast Cancer: Leveraging Clinical Pathways to Navigate a Complex Treatment Landscape:Подробнее

The evolving role of antibody-drug conjugates in the treatment of urothelial carcinomaПодробнее

Antibody Drug Conjugates for CancerПодробнее

Ask the Expert: Advances in Metastatic Breast CancerПодробнее

Tackling the Practicalities of Antibody–Drug Conjugate Therapy for Solid TumorsПодробнее